CA3067057A1 - Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) - Google Patents

Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)

Info

Publication number
CA3067057A1
CA3067057A1 CA3067057A CA3067057A CA3067057A1 CA 3067057 A1 CA3067057 A1 CA 3067057A1 CA 3067057 A CA3067057 A CA 3067057A CA 3067057 A CA3067057 A CA 3067057A CA 3067057 A1 CA3067057 A1 CA 3067057A1
Authority
CA
Canada
Prior art keywords
gfap
uch
reference level
sample
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067057A
Other languages
English (en)
French (fr)
Inventor
Beth MCQUISTON
Saul Datwyler
Raj CHANDRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA3067057A1 publication Critical patent/CA3067057A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02015—Ubiquitin thiolesterase (3.1.2.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CA3067057A 2017-12-09 2018-12-07 Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) Pending CA3067057A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762596805P 2017-12-09 2017-12-09
US62/596,805 2017-12-09
US201762611707P 2017-12-29 2017-12-29
US62/611,707 2017-12-29
US201862652734P 2018-04-04 2018-04-04
US62/652,734 2018-04-04
PCT/US2018/064587 WO2019113525A2 (en) 2017-12-09 2018-12-07 Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)

Publications (1)

Publication Number Publication Date
CA3067057A1 true CA3067057A1 (en) 2019-06-13

Family

ID=64901115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067057A Pending CA3067057A1 (en) 2017-12-09 2018-12-07 Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)

Country Status (8)

Country Link
US (3) US11022617B2 (https=)
EP (1) EP3721233A2 (https=)
JP (1) JP7344801B2 (https=)
CN (1) CN111094983A (https=)
AU (1) AU2018378971B9 (https=)
BR (1) BR112019028254A2 (https=)
CA (1) CA3067057A1 (https=)
WO (1) WO2019113525A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2665245T3 (es) * 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
BR112019021612A2 (pt) 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
US10877038B2 (en) 2017-04-28 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
JP7416625B2 (ja) 2017-05-25 2024-01-17 アボット・ラボラトリーズ 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
BR112019025313A2 (pt) 2017-05-30 2020-06-23 Abbott Laboratories Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
CA3084064A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2022119917A1 (en) * 2020-12-01 2022-06-09 Hay Meredith Biomarker and treatment for vascular cognitive impairment and related conditions
EP4341699A1 (en) * 2021-05-18 2024-03-27 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
JP2024521476A (ja) * 2021-06-14 2024-05-31 アボット・ラボラトリーズ 音響エネルギー、電磁エネルギー、過圧波及び／又は爆風により引き起こされる脳損傷の診断法又は診断の一助となる方法
CN118715440A (zh) * 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
AU2022339759A1 (en) * 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023056268A1 (en) * 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
FI130340B (en) * 2022-02-22 2023-06-29 Medicortex Finland Oy Procedure for the diagnosis of traumatic brain injury
JP2025524496A (ja) 2022-06-29 2025-07-30 アボット・ラボラトリーズ 生体試料におけるｇｆａｐを決定するための磁気ポイントオブケアシステム及びアッセイ
CN118707112B (zh) * 2024-08-28 2024-12-13 浙江格物致知生物科技有限公司 一种gfap、nfl和uch-l1联合检测试剂盒及其用于脑创伤早期检测

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5635600A (en) 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
ATE111083T1 (de) 1986-10-22 1994-09-15 Abbott Lab Chemilumineszierende acridinium- und phenantridiniumsalze.
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2148225T3 (es) 1992-03-30 2000-10-16 Abbott Lab Reactivos y procedimientos que permiten la deteccion y la cuantificacion de la tiroxina en muestras de fluido.
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
JPH09510201A (ja) 1994-03-07 1997-10-14 メダレツクス・インコーポレーテツド 臨床的効用を有する二重特異性分子
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0826034A4 (en) 1995-04-21 2002-06-19 Cell Genesys Inc PRODUCTION OF LARGE GENOMIC DNA DELETIONS
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6017517A (en) 1996-12-18 2000-01-25 The Dial Corporation Method for treating human nails
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6682928B2 (en) 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US6438498B1 (en) 2000-02-10 2002-08-20 I-Stat Corporation System, method and computer implemented process for assaying coagulation in fluid samples
TWI335336B (https=) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
DK1438400T3 (da) 2001-10-01 2009-10-05 Dyax Corp Flerkædede eukaryote display-vektorer og anvendelser deraf
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20060134713A1 (en) 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
DK2357477T3 (en) 2003-09-20 2018-02-05 Electrophoretics Ltd Diagnostic approach for brain injury-related disorders based on detection of NDKA
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
EP2207033B1 (en) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
JP2008526251A (ja) 2005-01-18 2008-07-24 バイオセプト インコーポレイティッド パターン化されたポストを有するマイクロチャネルを用いた細胞分離
KR20080027392A (ko) 2005-07-14 2008-03-26 나노디텍 코포레이션 미세유체장치와 미세유체장치의 제작 및 사용방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN101983337A (zh) 2008-02-04 2011-03-02 班扬生物标记公司 用于诊断或治疗脑损伤的方法
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
ES2665245T3 (es) * 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
ES2612507T3 (es) 2009-03-06 2017-05-17 President And Fellows Of Harvard College Dispositivos microfluídicos y electroquímicos
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
EP3355059A3 (en) 2009-06-19 2018-09-26 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120202231A1 (en) 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
WO2011160096A2 (en) 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
EP2628013B1 (en) 2010-10-14 2019-06-12 The Johns Hopkins University Biomarkers of brain injury
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
US20120322682A1 (en) 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
WO2013090285A1 (en) 2011-12-14 2013-06-20 University Of Rochester Method of diagnosing mild traumatic brain injury
WO2014124174A2 (en) 2013-02-08 2014-08-14 Children's Hospital Los Angeles Circulating bmec and related cells as biomarkers of cns diseases associated with the blood-brain-barrier disorders
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
US9265441B2 (en) 2013-07-12 2016-02-23 Siemens Aktiengesellschaft Assessment of traumatic brain injury
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
US20150224499A1 (en) 2014-02-13 2015-08-13 SFC Fluidics, Inc. Automated Microfluidic Sample Analyzer Platforms for Point of Care
US20170023591A1 (en) * 2014-04-07 2017-01-26 Iron Horse Diagnostics, Inc. Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems
RU2020129667A (ru) 2014-09-22 2020-10-08 Японское Агентство По Науке И Технике Способ детектирования молекулы-мишени и набор для использования в этом способе
WO2016055148A2 (en) 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury
BR112017021256A2 (pt) 2015-04-03 2018-06-26 Abbott Laboratories dispositivos e métodos para a análise de amostras
WO2016161402A1 (en) 2015-04-03 2016-10-06 Abbott Laboratories Devices and methods for sample analysis
FI20155280L (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
EP3304090A4 (en) 2015-05-29 2018-11-07 Cedars-Sinai Medical Center Correlated peptides for quantitative mass spectrometry
CN105085629A (zh) 2015-08-12 2015-11-25 浙江聚康生物工程有限公司 人gfap抗原决定簇多肽、抗体及其体外诊断试剂盒
JP2019535015A (ja) 2016-10-03 2019-12-05 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2018136825A1 (en) 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Highly multiplexed and mass spectrometry based methods to measuring 72 human proteins
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
BR112019021612A2 (pt) * 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
US10877038B2 (en) * 2017-04-28 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2018217792A1 (en) 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
JP7416625B2 (ja) 2017-05-25 2024-01-17 アボット・ラボラトリーズ 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
BR112019025313A2 (pt) 2017-05-30 2020-06-23 Abbott Laboratories Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
CN107202890A (zh) * 2017-05-31 2017-09-26 湖州华远生物技术有限公司 用于轻中度脑损伤的快速诊断试剂及含有该试剂的试剂盒及该试剂盒的制备和检测方法
US20190091687A1 (en) 2017-09-28 2019-03-28 Maha Abdullah A. Alhasnani Safe blood pregnancy test at home
US11016105B2 (en) * 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
US11022617B2 (en) * 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
CA3084064A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
US20190302127A1 (en) 2018-03-30 2019-10-03 Sysmex Corporation Method for diagnosing traumatic brain injury
WO2019199869A1 (en) 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in physiological samples
US20220288588A1 (en) 2019-08-05 2022-09-15 Auer Precision Company, Inc. Microfluidic passive plasma separation device and method
KR102464243B1 (ko) 2020-04-01 2022-11-08 프리시젼바이오 주식회사 외상성 뇌손상 바이오마커 검출용 시분해 형광분석 측방유동 분석장치 및 이를 이용한 외상성 뇌손상 바이오마커 측정방법

Also Published As

Publication number Publication date
US11022617B2 (en) 2021-06-01
AU2018378971A1 (en) 2020-01-02
US20250020666A1 (en) 2025-01-16
AU2018378971B2 (en) 2025-04-03
WO2019113525A3 (en) 2019-07-11
EP3721233A2 (en) 2020-10-14
WO2019113525A2 (en) 2019-06-13
JP7344801B2 (ja) 2023-09-14
US20210356477A1 (en) 2021-11-18
BR112019028254A2 (pt) 2020-07-14
AU2018378971B9 (en) 2025-04-17
JP2021505843A (ja) 2021-02-18
US20190242906A1 (en) 2019-08-08
US12105098B2 (en) 2024-10-01
CN111094983A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
US12105100B2 (en) Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
US20250020665A1 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
US20250020672A1 (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
US12105098B2 (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
US20250020649A1 (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2023034777A1 (en) Methods and systems of diagnosing brain injury
US20220381796A1 (en) Methods of evaluating brain injury in a pediatric subject
CA3053410C (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
CA3053409C (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
CA3059601A1 (en) Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240819

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250417

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250417

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251112

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D141 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CONDITIONAL ALLOWANCE

Effective date: 20260410

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260410

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTERNAL INVESTIGATION REQUEST

Effective date: 20260413